HIV immunotherapeutics

Chemistry: molecular biology and microbiology – Micro-organism – tissue cell culture or enzyme using process... – Recombinant dna technique included in method of making a...

Patent

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

4353201, 435 697, 4352523, 536 2353, 536 234, C12N 120, C12N 1513, C07H 2104

Patent

active

056655690

DESCRIPTION:

BRIEF SUMMARY
BACKGROUND

The present invention relates, in general, to materials and methods useful in the prevention and treatment of Human Immunodeficiency Virus (HIV-1) infection. More particularly, the invention relates to monoclonal antibodies useful in passive immunization of HIV-1 susceptible or infected animals, especially humans.
The infective process of HIV-1 in vivo has recently been the subject of a review article by McCune, Cell, 64, pp. 351-363 (1991). Briefly, HIV-1 infects a variety of cell lineages, such as T-cells, monocytes/macrophages and neuronal cells, which express the CD4 receptor. Because the vast majority of CD4.sup.+ cells in the body are "resting" or quiescent and divide only in response to specific signals, infection with HIV-1 results in CD4.sup.+ cells harboring transcriptionally inactive virus. Stimulation of the immune system of infected animals, including active immunization, may result in polyclonal activation and the signaling of resting CD4.sup.+ cells to go into the S phase of the cell cycle. The replicating cells then actively produce viral particles, provoking spread of the infection. Considering this negative effect of stimulating the immune system of an HIV-1-infected animal, it is possible that the most effective method of preventing or treating HIV-1 infection is passive immunization, that is, administering anti-HIV-1 antibodies to a susceptible or infected animal.
Jackson et al., Lancet, 2, pp. 647-652 (1988) reports that a single administration of anti-HIV-I antibodies in the form of plasma to human patients afflicted with advanced acquired immunodeficiency syndrome (AIDS, the syndrome of progressive immune system deterioration associated with HIV-I infection) temporarily resulted in: fewer symptoms, a transient increase in T lymphocytes, a reduction in the frequency of opportunistic infections and a decline in the rate at which HIV-1 could be cultured from plasma or lymphocytes of the patients. See also, Karpas et al., Proc. Nat. Acad. Sci. USA, 85, pp. 9234-9237 (1988). Moreover, Emini et al., Nature, 355, pp. 728-730 (1992) reports that the administration of an antibody specifically reactive with HIV-1 to a chimpanzee before the animal was exposed to HIV-1 resulted in the chimpanzee remaining free of signs of viral infection. These studies indicate that antibodies capable of neutralizing HIV-1 can be useful in the prevention/treatment of HIV-1 infection.
The HIV-1 major external envelope glycoprotein, gp120, binds to the cellular CD4 receptor and facilitates the internalization of the virus. Several epitopes of the glycoprotein have been associated with the development of neutralizing antibodies. Ho et al., Science, 239, pp. 1021-1023 (1988) reports that amino acids 254-274 of gp120 elicit polyclonal antisera capable of group-specific neutralization of three different isolates of HIV-1. Conformation-dependent epitopes, epitopes not consisting of primary sequences of amino acids, on gp120 have also been implicated in eliciting antibodies that neutralize diverse strains of the virus by Haigwood et al., Vaccines 90, pp. 313-320 (1990) and Ho et al., J. Virol., 65(1), pp. 489-493 (1991). The so-called "principal neutralizing determinant" (PND) of HIV-1 gp120 has been localized to the "V.sub.3 loop" of gp120. See Putney et al., Science, 234, pp. 1392-1395 (1986); Rusche et al., Proc. Natl. Acad. Sci. USA, 85, pp. 3198-3202 (1988); Goudsmit et al., Proc. Natl. Acad. Sci. USA, 85, pp. 4478-4482 (1988); Palker et al., Proc. Natl. Acad. Sci. USA, 85, pp. 1932-1936 (1988); and Holley et al., Proc. Natl. Acad. Sci. USA, 85 ,pp. 6800-6804 (1991). The V.sub.3 loop consists of a hypervariable domain which is established by disulfide bonding between cysteine residues flanking the domain. The V.sub.3 loop of HIV-1.sub.MN, for example, is formed by a disulfide bond between the cysteine residues at positions 302 and 336 of gp120.
Recombinant and synthetic protein fragments including the series of amino acid residues of the V.sub.3 loop from various HIV isolates have been reported to elici

REFERENCES:
patent: 5019387 (1991-05-01), Haynes et al.
Ohno et al. PNAS vol. 88 p. 10726 1991.
Fahey et al. Clin. Exp. Immun. 1992 88, 165.
Akerblom et al., "Neutralizing cross-reactive and non-neutralizing monoclonal antibodies to HIV-1 gp120", AIDS, 4:953-960 (1990).
Banapour et al., "The AIDS-Associated Retrovirus is Not Sensitive to Lysis or Inactivation by Human Serum", Virology, 152:268-271.
Bartholomew et al., "Lysis of Oncornaviruses by Human Serum", J. Exp. Med., 147:844-853 (1978).
Cheng-Mayer et al., "Human Immunodeficiency Virus Can Productively Infect Cultured Human Glial Cells", Proc. Natl. Acad. Sci. USA, 84:3526-3530 (1987).
Chothia et al., "Canonical Structures for the Hypervariable Regions of Immunoglobulins", J. Mol. Biol., 196:901-917 (1987).
Cooper et al., "Lysis of RNA Tumor Viruses by Human Serum: Direct Antibody-Independent Triggering of the Classical Complement Pathway", J. Exp. Med., 144:970-984 (1976).
Durda et al., "HIV-1 Neutralizing Monoclonal Antibodies Induced by a Synthetic Peptide", AIDS Research and Human Retroviruses, 6:1115-1123 (1990).
Emini et al., "Prevention of HIV-1 Infection in Chimpanzees by gp120 V3 Domain-Specific Monoclonal Antibody", Nature, 355:728-730 (1992).
Epp et al., "Crystal and Molecular Structure of a Dimer Composed of the Variable Portions of the Bence-jones Protein REI", Eur. J. Biochem., 45:513-524 (1974).
Foote et al., "Antibody Framework Residues Affecting the Conformation of the Hypervarible Loops", J. Mol. Biol., 224:487-499 (1992).
Godding, "Antibody Production by Hybridomas", J. Immunol. Meth., 39:285-308 (1980).
Goudsmit et al., "Human Imunodeficiency Virus Type 1 Neutralization Epitome With Conserved Architecture Elicits Early Type-Specific Antibodies in Experimentally Inflected Chimpanzees", Proc. Natl. Acad. Sci. USA, 85:4478-4482 (1988).
Haigwood et al., "Evidence for Neutralizing Antibodies Directed Against Conformational Epitopes of HIV-1 gp120", Vaccines, 90:313-320 (1990).
Halstead et al., "Antibody-Enhanced Dengue Virus Infection in Primate Leukocytes", Nature, 265:739-741 (1977).
Ho et al., "Second Conserved Domain of gp120 Is Important for HIV Infectivity and Antibody Neutralization", Science, 239:1021-1023 (1988).
Holey et al., "Prediction of Optimal Peptide Mixtures to Induce Broadly Neutralizing Antibodies to Human Immunodefiency Virus Type 1", Proc. Natl. Acad. Sci. USA, 85:6800-6804 (1991).
Jackson et al., "Passive Immunoneutralisation of Human Immunodeficiency Virus in Patients with Advanced AIDS", Lancet, 2:647-652 (1988).
Javaherian et al., "Broadley Neutralizing Antibodies Elicited by the Hypervariable Neutralizing Determinant of HIV-1", Science, 250:1590-1593 (1990).
Javaherian et al., "Principal Neutralizing Domain of the Human Immunodeficiency Virus Type 1 Envelope Protein", Proc. Natl. Acad. Sci. USA, 86:6768-6772 (1989).
Johnson et al., "HIV-Infected Cell Fusion Assay", Techniques in HIV-1 Research, Stockton Press, New York, NY, pp. 92-97 (1990).
Kabat et al., "Sequences of Protein of Immunological Interest", 5th Edition, U.S. Department of Health and Human Services, U.S. Government Printing Office (1991) `Table of Contents`.
Karpas et al., "effects of Passive immunization in Patients with the Acquired Immunodeficiency Syndrome-Related Complex and Acquired Immunodeficiency Syndrome", Proc. Natl. Acad. Sci. USA, 85:9234-9237 (1988).
LaRosa et al., "Conserved Sequence and Structural Elements in the HIV-1 Principal Neutralizing Determinant", Science, 249:932-935 (1990).
Lasky et al., "Neutralization of the AIDS Retrovirus by Antibodies to a Recombinant Envelope Glycoprotein", Science, 233:209-212 (1986).
Liou et al., "A Chimeric Mouse-Human Antibody that Retains Specificity for HIV gp120 and Mediates the Lysis of HIV-Infected Cells", J. Immunol., 143(12):3967-3975 (1989).
Matsushita et al., "Characterization of a Human Immunodeficency Virus Neutralizing Monoclonal Antibody and Mapping of the Neutralizing Epitope", J. Virol., 62:2107-2114 (1988).
McCune, "HIV-1: The In

LandOfFree

Say what you really think

Search LandOfFree.com for the USA inventors and patents. Rate them and share your experience with other people.

Rating

HIV immunotherapeutics does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with HIV immunotherapeutics, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and HIV immunotherapeutics will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFUS-PAI-O-68943

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.